Sign Out
GLUCOVANCE 250 mg/1.25 mg is indicated as initial therapy, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed with diet and exercise alone.
GLUCOVANCE 500 mg/2.5 mg, 500 mg/5 mg and 1000/5mg is indicated as second-line therapy when diet, exercise, and initial treatment with a sulfonylurea or metformin do not result in adequate glycemic control in patients with type 2 diabetes.
